{{medical}}{{TA|G1=ME|G2=LS}}{{Drugbox
| verifiedrevid = 460111438
| IUPAC_name = (1''R'',3a''S'',3b''R'',7a''R'',8a''S'',8b''S'',8c''S'',10a''S'')-1-Acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[''a'']cyclopropa[''g'']phenanthren-1-yl acetate
| image = Cyproterone_acetate.svg
| width = 230
| image2 =Acetato de ciproterona3D.png

<!--Clinical data-->
| tradename = Androcur、Cyprostat、Siterone、色普龙、安得卡等
| Drugs.com = {{drugs.com|CONS|cyproterone}}
| pregnancy_category = X
| legal_status = Rx-only
| routes_of_administration = [[口服给药|口服给药]], [[肌肉注射|肌肉注射]]

<!--Pharmacokinetic data-->
| bioavailability = 100%
| protein_bound = 96%
| metabolism = [[肝臟|肝臟]]
| elimination_half-life = 40小时
| excretion = 60%胆，33%肾

<!--Identifiers-->
| IUPHAR_ligand = 2865
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 427-51-0
| ATC_prefix = G03
| ATC_suffix = HA01
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 139835
| PubChem = 9880
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 9496
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4KM2BN5JHF
| KEGG_Ref = 
| KEGG = 
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 50743

<!--Chemical data-->
| C = 24 | H = 29 | Cl = 1 | O = 4
| molecular_weight = 416.94 g/mol
|  smiles = O=C4\C=C3\C(\Cl)=C/[C@@H]1[C@H](CC[C@@]2([C@@](OC(=O)C)(C(=O)C)CC[C@@H]12)C)[C@@]3(C)[C@H]5C[C@@H]45
|  StdInChI = 1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1
|  StdInChIKey = UWFYSQMTEOIJJG-FDTZYFLXSA-N
}}
{{expand English|Cyproterone acetate}}

'''醋酸环丙孕酮'''（<span>Cyproterone acetate，'''[[CPA|CPA]]'''），商品名有如'''色普龙'''、'''Androcur'''、'''安得卡'''等，是一种[[有机化合物|合成]][[甾體|甾体]][[抗雄激素|抗雄激素]]、[[黄体制剂|黄体制剂]]、[[抗促性腺激素|抗促性腺激素]]。</span><ref name="pmid2949114">{{Cite journal|title=Pharmacology of antiandrogens|author=Neumann F, Töpert M|date=November 1986|journal=Journal of Steroid Biochemistry|issue=5B|doi=10.1016/0022-4731(86)90320-1|volume=25|pages=885–95|pmid=2949114}}</ref> 因其阻止[[内源|内源]]雄激素与其[[雄激素受体|受体]]结合以及抑制雄激素[[生物合成|生物合成]]的抗[[雄激素|雄]]作用，此药主要用于[[雄激素相关病况|雄激素相关病况]]的治疗。<ref name="Berek2007">{{Cite book|url=http://books.google.com/books?id=P3erI0J8tEQC&pg=PA1085|title=Berek & Novak's Gynecology|publisher=Lippincott Williams & Wilkins|year=2007|isbn=978-0-7817-6805-4|page=1085|author=Jonathan S. Berek}}</ref> 有时也会使用CPA的[[孕激素|孕激素]]样作用，例如达英–35（{{Lang-en|Diane-35}}）这种[[复合口服避孕药|复合口服避孕药]]就是此药和[[炔雌醇|炔雌醇]]复配而成。<ref name="HumansOrganization2007">{{Cite book|url=http://books.google.com/books?id=aGDU5xibtNgC&pg=PA437|title=Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy|publisher=World Health Organization|year=2007|isbn=978-92-832-1291-1|page=437|author1=IARC Working Group on the Evaluation of Carcinogenic Risks to Humans|author2=World Health Organization|author3=International Agency for Research on Cancer}}</ref>

== 医疗用途 ==
CPA自1964年来就作为抗雄药剂使用，且是第一个用于临床的抗雄药。<ref name="Wakelin2002">{{Cite book|url=http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32|title=Systemic Drug Treatment in Dermatology: A Handbook|date=1 June 2002|publisher=CRC Press|isbn=978-1-84076-013-2|page=32|author=Sarah H. Wakelin}}</ref>此药在[[欧洲|欧洲]]广泛使用，在[[加拿大|加拿大]]、[[墨西哥|墨西哥]]等国家亦有使用。 由于对肝毒性的担忧，[[美国食品药品监督管理局|美国食品药品监督管理局]]并未批准此药，于是在美国使用[[甲羥孕酮|甲羥孕酮]]取而代之。<ref name="DukerMalsch2013">{{Cite book|url=http://books.google.com/books?id=OfGlANwlHAEC&pg=PT77|title=Incapacitation: Trends and New Perspectives|date=28 January 2013|publisher=Ashgate Publishing, Ltd.|isbn=978-1-4094-7151-6|page=77|author1=Dr Marius Duker|author2=Dr Marijke Malsch}}</ref>CPA已被批准用于[[乳腺癌|乳腺癌]]、 [[性早熟|性早熟]]、与雄激素相关的[[皮肤病|皮肤病]]（如[[粉刺|粉刺]]、[[脂溢性皮炎|脂溢性皮炎]]、[[雄激素性脱发|雄激素性脱发]]），以及降低[[性罪犯|性罪犯]]的[[性冲动|性冲动]]。<ref name="Maggi2011">{{Cite book|url=http://books.google.com/books?id=in_DuQFgcJMC&pg=PA104|title=Hormonal Therapy for Male Sexual Dysfunction|date=17 November 2011|publisher=John Wiley & Sons|isbn=978-1-119-96380-6|page=104|author=Mario Maggi}}</ref>CPA与炔雌醇复方（有时称作co-cyprindiol）自1997年来也作为[[激素避孕|避孕药]]出售。<ref name="Wakelin2002">{{Cite book|url=http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32|title=Systemic Drug Treatment in Dermatology: A Handbook|date=1 June 2002|publisher=CRC Press|isbn=978-1-84076-013-2|page=32|author=Sarah H. Wakelin}}</ref>

CPA的其他适应症有[[良性前列腺增生症|良性前列腺增生症]]、[[陰莖異常勃起|陰莖異常勃起]]、[[性慾亢進|性慾亢進]]、[[性偏離|性偏離]]、[[潮熱|潮熱]]、女性[[雄激素过剩|雄激素过剩]]等。此外，CPA也广泛用于[[跨性別女性|跨性别女性]]的[[性别肯定激素治疗|性别肯定激素治疗]]（GAHT），美国由于未批准使用此药，一般则会使用[[螺内酯|螺内酯]]，一种具有抗雄作用的[[利尿剂|利尿剂]]。<ref name="JamesonKretser2013">{{Cite book|url=http://books.google.com/books?id=Np8xxP6pcdUC&pg=RA1-PT476|title=Endocrinology Adult and Pediatric: Reproductive Endocrinology|date=7 May 2013|publisher=Elsevier Health Sciences|isbn=978-0-323-22152-8|author1=J. Larry Jameson|author2=David M. de Kretser|author3=John C. Marshall|author4=Leslie J. De Groot}}</ref>

=== 调查中 ===
CPA可能对强迫症有效。<ref name="Rapoport1989">{{Cite book|url=http://books.google.com/books?id=MctlHlE3470C&pg=PA229|title=Obsessive-compulsive Disorder in Children and Adolescents|date=1 January 1989|publisher=American Psychiatric Pub|isbn=978-0-88048-282-0|pages=229–231|author=Judith L. Rapoport}}</ref>在非常有限的临床研究报告中，CPA对女性强迫症“相当有效”。<ref name="pmid20623923">{{Cite journal|title=Drug treatment of obsessive-compulsive disorder|url=|journal=Dialogues Clin Neurosci|issue=2|doi=|year=2010|volume=12|pages=187–97|pmc=3181958|pmid=20623923|vauthors=Kellner M}}</ref><ref name="IborCercós2004">{{Cite book|url=http://books.google.com/books?id=wNIJ4rs7cnEC&pg=PA376|title=Images of Spanish Psychiatry|publisher=Editorial Glosa, S.L.|year=2004|isbn=978-84-7429-200-8|pages=376–|author1=Juan José López Ibor|author2=Carmen Leal Cercós|author3=Carlos Carbonell Masiá}}</ref>

== 副作用 ==

=== 女性化 ===
CPA的抗雄及抗促性腺激素作用在男性中直接造成的副作用有身体[[去雄性化|去雄性化]]、[[雌性化|雌性化]]、[[男性乳房发育症|乳房发育]]、[[乳房疼痛|乳房疼痛]]、[[乳溢症|乳溢症]]、[[性功能障碍|性功能障碍]]（包括[[性欲|性欲]]减退和[[勃起功能障碍|勃起功能障碍]]）、[[精子发生|生精]]障碍和可逆转的[[不育|不育]]。<ref name="Wakelin2002">{{Cite book|url=http://books.google.com/books?id=F1ZiAgAAQBAJ&pg=PA32|title=Systemic Drug Treatment in Dermatology: A Handbook|date=1 June 2002|publisher=CRC Press|isbn=978-1-84076-013-2|page=32|author=Sarah H. Wakelin}}</ref>在前列腺癌治疗中，CPA被男性患者称为能造成如手术[[阉割|阉割]]一般“严重”的性欲和勃起功能减退。<ref name="IversenMelezinek2001">{{Cite journal|title=Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function|url=https://archive.org/details/sim_bju-international_2001-01_87_1/page/47|last2=Melezinek|first2=I.|journal=BJU International|issue=1|doi=10.1046/j.1464-410x.2001.00988.x|year=2001|volume=87|pages=47–56|issn=1464-4096|pmid=11121992|last3=Schmidt|first3=A.|last1=Iversen|first1=P.}}</ref>

=== 抑郁 ===
现已发现CPA在男女中皆与[[抑郁|抑郁]]率升高相关。<ref name="Blume-PeytaviWhiting2008">{{Cite book|url=http://books.google.com/books?id=pHrX2-huQCoC&pg=PA181|title=Hair Growth and Disorders|date=26 June 2008|publisher=Springer Science & Business Media|isbn=978-3-540-46911-7|pages=181–|author1=Ulrike Blume-Peytavi|author2=David A. Whiting|author3=Ralph M. Trüeb}}</ref>有报告称使用此药治疗多毛症（剂量25–100 mg）的女性中，可能有多达20–30%显示抑郁症状。<ref name="Barrett2007">{{Cite book|url=http://books.google.com/books?id=I-8qZlGIpnQC&pg=PA174|title=Transsexual and Other Disorders of Gender Identity: A Practical Guide to Management|publisher=Radcliffe Publishing|year=2007|isbn=978-1-85775-719-4|page=174|author=James Barrett}}</ref><ref name="BarthCherry1991">{{Cite journal|title=Cyproterone acetate for severe hirsutism:results of a double-blind dose-ranging study|url=https://archive.org/details/sim_clinical-endocrinology_1991-07_35_1/page/5|last2=Cherry|first2=C. A.|journal=Clinical Endocrinology|issue=1|doi=10.1111/j.1365-2265.1991.tb03489.x|year=1991|volume=35|pages=5–10|issn=0300-0664|last3=Wojnarowska|first3=F.|last4=Dawber|first4=R. P. R.|last1=Barth|first1=J. H.}}</ref>同时，也有研究发现大约20%的服用Dianette牌口服避孕药（只含2 mg CPA）的女性发生抑郁。<ref name="Rushton2002">{{Cite journal|title=Nutritional factors and hair loss|journal=Clinical and Experimental Dermatology|issue=5|doi=10.1046/j.1365-2230.2002.01076.x|year=2002|volume=27|pages=396–404|issn=0307-6938|last1=Rushton|first1=D. H.}}</ref>，和接受更具选择性的[[GnRH类似物|GnRH类似物]]（一般不认为有显著抑郁风险，持续雌激素补充的话）治疗的跨性别女性相比，使用CPA作为GAHT的抗雄成分的患者也有高得多的出现抑郁症状的风险，且此风险与CPA关联。<ref name="SealFranklin2012">{{Cite journal|title=Predictive Markers for Mammoplasty and a Comparison of Side Effect Profiles in Transwomen Taking Various Hormonal Regimens|last2=Franklin|first2=S.|journal=The Journal of Clinical Endocrinology & Metabolism|issue=12|doi=10.1210/jc.2012-2030|year=2012|volume=97|pages=4422–4428|issn=0021-972X|last3=Richards|first3=C.|last4=Shishkareva|first4=A.|last5=Sinclaire|first5=C.|last6=Barrett|first6=J.|last1=Seal|first1=L. J.}}</ref>CPA的抑郁作用可能与其糖皮質激素、抗雄激素、和/或抗促性腺激素作用有关，毕竟糖皮质激素、抗雄激素（对男性来说）以及GnRH类似物都和抑郁有关联。<ref name="Boccardo2000">{{Cite journal|title=Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?|journal=Critical Reviews in Oncology/Hematology|issue=2|doi=10.1016/S1040-8428(00)00051-2|year=2000|volume=35|pages=121–132|issn=1040-8428|last1=Boccardo|first1=Francesco}}</ref><ref name="Peedell2005">{{Cite book|url=http://books.google.com/books?id=z-ljkq6Fv5kC&pg=PA81|title=Concise Clinical Oncology|publisher=Elsevier Health Sciences|year=2005|isbn=0-7506-8836-X|pages=81–|author=Clive Peedell}}</ref><ref name="Damber2005">{{Cite journal|title=Endocrine therapy for prostate cancer|url=https://archive.org/details/sim_acta-oncologica_2005_44_6/page/605|journal=Acta Oncologica|issue=6|doi=10.1080/02841860510029743|year=2005|volume=44|pages=605–609|issn=0284-186X|last1=Damber|first1=Jan-Erik}}</ref><ref name="Lahita2004">{{Cite book|url=http://books.google.com/books?id=FPj1IT9xy2wC&pg=PA797|title=Systemic Lupus Erythematosus|date=9 June 2004|publisher=Academic Press|isbn=978-0-08-047454-0|pages=797–|author=Robert G. Lahita}}</ref>CPA造成的[[维生素B12缺乏症|维生素B12缺乏症]]也有可能是一个很重要的因素。<ref name="Rushton2002">{{Cite journal|title=Nutritional factors and hair loss|journal=Clinical and Experimental Dermatology|issue=5|doi=10.1046/j.1365-2230.2002.01076.x|year=2002|volume=27|pages=396–404|issn=0307-6938|last1=Rushton|first1=D. H.}}</ref>由于抑郁的副作用，在将CPA用于有抑郁症病史的患者时应特别小心，特别是当抑郁病史严重之时。<ref name="WakelinMaibach2015">{{Cite book|url=http://books.google.com/books?id=fCysCQAAQBAJ&pg=PA34|title=Handbook of Systemic Drug Treatment in Dermatology, Second Edition|date=21 May 2015|publisher=CRC Press|isbn=978-1-4822-2286-9|pages=34–|author1=Sarah H. Wakelin|author2=Howard I. Maibach|author3=Clive B. Archer}}</ref>

=== 血栓 ===
当单独使用时，CPA对[[凝血因子|凝血因子]]并没有表现出什么显著作用。然而在口服避孕药之类的情况下与炔雌醇联用时，便会提升发生[[深静脉血栓|深静脉血栓]]的风险。<ref>{{Cite journal|title=Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives|author=Vasilakis-Scaramozza C, Jick H|journal=Lancet|issue=9291|doi=10.1016/S0140-6736(01)06522-9|year=2001|volume=358|pages=1427–9|pmid=11705493}}</ref>服用含有CPA的避孕药的女性和不服用的女性相比，[[血栓形成|血栓形成]]的概率提升六到七倍，与服用含左炔诺孕酮避孕药的女性比则为两倍。<ref>{{Cite journal|title=Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses|author=Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E|last2=Nielsen|first2=L. H.|journal=BMJ|doi=10.1136/bmj.d6423|year=2011|volume=343|pages=1–15|pmc=3202015|pmid=22027398|last3=Skovlund|first3=C. W.|last4=Skjeldestad|first4=F. E.|last5=Lokkegaard|first5=E.}}</ref>

=== 肝毒性 ===
CPA的最严重的潜在副作用为其[[肝毒性|肝毒性]]。因此，服用CPA的患者，尤其是高剂量服用者（每日超过50–100 mg甚至200–300 mg），应该持续监视[[肝功能测试|肝功能测试]]结果。<ref name="Berlex">{{Cite web|url=http://www.berlex.ca/html/docs/en/AndrocurEn.pdf|title=Cyproterone Acetate Tablets and Injections Product Monographs (revised version)|author=Berlex Canada, Inc.|date=2003-02-10|format=PDF|deadurl=yes|archiveurl=https://web.archive.org/web/20060924152720/http://www.berlex.ca/html/docs/en/AndrocurEn.pdf|archivedate=2006-09-24}}</ref>CPA的毒性取决于剂量，口服避孕药中2 mg那么低的剂量并没有显现出多少风险。<ref>{{Cite web|url=http://www.tga.gov.au/adr/aadrb/aadr0402.htm|title=Australian Adverse Drug Reactions Bulletin, Volume 23, Number 1|author={{tsl|en|Adverse Drug Reactions Advisory Committee||Adverse Drug Reactions Advisory Committee}}|date=February 2004|deadurl=yes|archiveurl=https://web.archive.org/web/20060904040039/http://www.tga.gov.au//adr/aadrb/aadr0402.htm|archivedate=2006-09-04}}</ref>

=== 脑膜瘤 ===
在很少见的情况下，高剂量（至少 25 mg/d）的CPA治疗与{{tsl|en|meningiomas||脑膜瘤}}的发生及恶化有关。此现象未见于低剂量的避孕药用途。<ref>{{Cite book|url=http://books.google.com/books?id=54rs2vTg51gC&pg=PA99|title=Meningeal Neoplasms—Advances in Research and Treatment: 2012 Edition: ScholarlyBrief|date=26 December 2012|publisher=ScholarlyEditions|isbn=978-1-4816-0002-6|pages=99–}}</ref><ref name="JamesonGroot2015">{{Cite book|url=http://books.google.com/books?id=xmLeBgAAQBAJ&pg=PT6225|title=Endocrinology: Adult and Pediatric|date=25 February 2015|publisher=Elsevier Health Sciences|isbn=978-0-323-32195-2|pages=6225–|author1=J. Larry Jameson|author2=Leslie J. De Groot}}</ref>因此，脑膜瘤或脑膜瘤病史为使用CPA的一个禁忌。<ref name="WakelinMaibach2015">{{Cite book|url=http://books.google.com/books?id=fCysCQAAQBAJ&pg=PA34|title=Handbook of Systemic Drug Treatment in Dermatology, Second Edition|date=21 May 2015|publisher=CRC Press|isbn=978-1-4822-2286-9|pages=34–|author1=Sarah H. Wakelin|author2=Howard I. Maibach|author3=Clive B. Archer}}</ref>

=== 杂项 ===
联合雌激素使用高剂量的CPA在跨性别女性中和强烈（高达400倍）的{{tsl|en|hyperprolactinemia||高催乳素血症}}有关。<ref name="OettelSchillinger2012">{{Cite book|url=http://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA544|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=544–|author1=Michael Oettel|author2=Ekkehard Schillinger}}</ref>对于同一群体，单独雌激素则只与少数单一的{{tsl|en|prolactinoma||催乳素瘤}}有关。<ref name="OettelSchillinger2012">{{Cite book|url=http://books.google.com/books?id=wBvyCAAAQBAJ&pg=PA544|title=Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-60107-1|pages=544–|author1=Michael Oettel|author2=Ekkehard Schillinger}}</ref>

由于对于[[雌激素|雌激素]]生产的抑制，长期高剂量使用CPA而不伴随雌激素可引发骨质酥松症，对两性皆然。<ref name="Priestman2012">{{Cite book|url=http://books.google.com/books?id=K41Lf91GULcC&pg=PA97|title=Cancer Chemotherapy in Clinical Practice|date=26 May 2012|publisher=Springer Science & Business Media|isbn=978-0-85729-727-3|pages=97–|author=Terrence Priestman}}</ref>

CPA也和{{tsl|en|stretch marks||妊娠纹}}生成有关，可能是由其[[糖皮质激素|糖皮质激素]]活性和/或其造成的{{tsl|en|dry skin||皮肤干燥}}导致。<ref>{{Cite journal|title=Cyproterone acetate and striae|author=Mohan D, Taylor R, Mackeith JA|journal=International Journal of Clinical Practice|issue=2|doi=10.3109/13651509809115348|year=1998|volume=2|pages=147–148|pmid=24946296}}</ref>

现已发现高剂量（至少 50–100 mg/d）服用CPA会导致[[维生素B12缺乏症|维生素B12缺乏症]]。<ref name="Trüeb2013">{{Cite book|url=http://books.google.com/books?id=JfE_AAAAQBAJ&pg=PA46|title=Female Alopecia: Guide to Successful Management|date=26 February 2013|publisher=Springer Science & Business Media|isbn=978-3-642-35503-5|pages=46–|author=Ralph M. Trüeb}}</ref><ref name="pmid2145099">{{Cite journal|title=Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia|url=https://archive.org/details/sim_clinical-and-experimental-dermatology_1990-07_15_4/page/277|journal=Clin. Exp. Dermatol.|issue=4|doi=|year=1990|volume=15|pages=277–81|pmid=2145099|vauthors=Ramsay ID, Rushton DH}}</ref> 在维生素B12缺乏症引发的多种症状中，由于[[单胺类神经递质|单胺类神经递质]]耗尽引发的[[焦慮|焦虑]]、[[应激性|应激性]]、[[疲倦|疲倦]]较值得注意，<ref name="SadockSadock2010">{{Cite book|url=http://books.google.com/books?id=EYWyr37ubwsC&pg=PT582|title=Kaplan and Sadock's Pocket Handbook of Clinical Psychiatry|publisher=Lippincott Williams & Wilkins|year=2010|isbn=978-1-60547-264-5|pages=582–|author1=Benjamin J. Sadock|author2=Virginia A. Sadock}}</ref><ref name="MusisiJacobson2015">{{Cite book|url=http://books.google.com/books?id=IfFICAAAQBAJ&pg=PA60|title=Brain Degeneration and Dementia in Sub-Saharan Africa|date=14 April 2015|publisher=Springer|isbn=978-1-4939-2456-1|pages=60–|author1=Seggane Musisi|author2=Stanley Jacobson}}</ref>此外也有证据提示此症可能与CPA治疗中常见的神经—精神（neuropsychiatric）不良反应有关。<ref name="Rushton2002">{{Cite journal|title=Nutritional factors and hair loss|journal=Clinical and Experimental Dermatology|issue=5|doi=10.1046/j.1365-2230.2002.01076.x|year=2002|volume=27|pages=396–404|issn=0307-6938|last1=Rushton|first1=D. H.}}</ref>因此，建议在大剂量CPA质量中监测血清维生素B12含量并适时补充。<ref name="Trüeb2013">{{Cite book|url=http://books.google.com/books?id=JfE_AAAAQBAJ&pg=PA46|title=Female Alopecia: Guide to Successful Management|date=26 February 2013|publisher=Springer Science & Business Media|isbn=978-3-642-35503-5|pages=46–|author=Ralph M. Trüeb}}</ref><ref name="pmid2145099">{{Cite journal|title=Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia|url=https://archive.org/details/sim_clinical-and-experimental-dermatology_1990-07_15_4/page/277|journal=Clin. Exp. Dermatol.|issue=4|doi=|year=1990|volume=15|pages=277–81|pmid=2145099|vauthors=Ramsay ID, Rushton DH}}</ref>

== 戒断 ==
对CPA的突然戒断可能有害。{{tsl|en|Schering AG||Schering AG}}的说明书建议逐步降低剂量，每隔几周降低一次，每次减少的每日用量不超过50 mg。对戒断主要的担忧来自CPA对[[肾上腺|肾上腺]]的影响。由于其糖皮质激素作用，高剂量的CPA可能会降低ACTH，从而在突然戒断时导致{{tsl|en|adrenal insufficiency||肾上腺皮质功能不全}}。此外，CPA虽然降低性腺的雄激素分泌，却能提升肾上腺的雄激素产生量，有时会甚至导致总体睾酮含量提升。<ref>{{Cite journal|title=Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone|author=van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH|journal=Contraception|issue=4|doi=10.1016/0010-7824(90)90034-S|year=1990|volume=41|pages=345–52|pmid=2139843}}</ref>因此，突然停止使用CPA可能导致意外的雄激素效果。{{citation needed|time=2016-10-07T13:21:37+00:00}}之所以有这个担忧是因为雄激素（特别是二氢睾酮）抑制肾上腺功能，进一步降低[[皮質類固醇|皮質類固醇]]生成。<ref>{{Cite journal|title=Inhibition of 3beta-hydroxysteroid dehydrogenase-isomerase in mouse adrenal cells: a direct effect of testosterone|url=https://archive.org/details/sim_steroids_2002-07_67_8/page/721|author=Stalvey JR|journal=Steroids|issue=8|doi=10.1016/S0039-128X(02)00023-5|year=2002|volume=67|pages=721–31|pmid=12117620}}</ref>

=== 肾上腺皮质功能不全 ===
有报道称醋酸环丙孕酮治疗中导致[[腎上腺|肾上腺功能]]抑制及[[促腎上腺皮質激素|促腎上腺皮質激素]]（ACTH）回应减弱的报告。这会导致肾上腺皮质功能不全，从而在停药时可能出现低[[皮質醇|皮质醇]]和[[醛固酮|醛固酮]]，以及较弱的ACTH反应。低醛固酮可能会导致低钠血症和高钾血症。服用醋酸环丙孕酮的患者应持续监测皮质醇和[[电解质|电解质]]情况，并在出现高钾血症时降低高钾含量食物的进食量，或是停止服药。<!-- 感觉前后有点矛盾？
 -->

===抗雄戒断综合症===
一些前列腺癌细胞会对醋酸环丙孕酮表现出一种截然不同的现象——这些细胞的[[雄激素受体|雄激素受体]]发生[[突变|突变]]，于是和平常情况下被醋酸环丙孕酮抑制不同，这些受体能被其激活。在这样的病例中，停止服用醋酸环丙孕酮反而可能减缓[[癌症|癌症]]生长。<ref>{{cite web | author=Prostate Cancer Research Institute. | title=The Anti-Androgen Withdrawal Response | url=http://www.prostate-cancer.org/education/andeprv/aawr.html | accessdate=2005-08-31 | deadurl=yes | archiveurl=https://web.archive.org/web/20050911070313/http://www.prostate-cancer.org/education/andeprv/aawr.html | archivedate=2005-09-11 }}</ref>

== 药理 ==

=== 活性概要 ===

已知醋酸环丙孕酮存在以下{{tsl|en|pharmacological activity||药理学活性}}：

* [[雄激素受体|雄激素受体]]（AR）[[受体拮抗剂|受体拮抗剂]]/极弱[[部分激动剂|部分激动剂]]<ref name="FiggChau2010">{{cite book | author1 = William Figg | author2 = Cindy H. Chau | author3 = Eric J. Small | title = Drug Management of Prostate Cancer | url = http://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71 | date = 14 September 2010 | publisher = Springer | isbn = 978-1-60327-829-4 | page = 71}}</ref>
* [[孕酮受体|孕酮受体]]（PR）[[激动剂|激动剂]]（K<sub>d</sub> = 15 nM; {{tsl|en|IC50||IC<sub>50</sub>}} = 79 nM）<ref name="FiggChau2010">{{cite book | author1 = William Figg | author2 = Cindy H. Chau | author3 = Eric J. Small | title = Drug Management of Prostate Cancer | url = http://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71 | date = 14 September 2010 | publisher = Springer | isbn = 978-1-60327-829-4 | page = 71}}</ref><ref name="pmid12695529"/>
* {{tsl|en|Glucocorticoid receptor||糖皮質激素受体}}（GR）[[受体拮抗剂|拮抗剂]]（K<sub>d</sub> = 45 nM; IC<sub>50</sub> = 360 nM）<ref name="pmid12695529" />
* {{tsl|en|21-Hydroxylase|21-羟化酶|}}、{{tsl|en|3β-hydroxysteroid dehydrogenase|3β-羟基类固醇脱氢酶|}}（3β-HSD）、{{tsl|en|17α-hydroxylase|17α-羟化酶|}}、{{tsl|en|17,20-lyase|17,20-裂解酶}}[[酶抑制剂|抑制剂]]<ref name="pmid2956461">{{cite journal |vauthors=Ayub M, Levell MJ | title = Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro | journal = Journal of Steroid Biochemistry | volume = 28 | issue = 1 | pages = 43–7 | date = July 1987 | pmid = 2956461 | doi = 10.1016/0022-4731(87)90122-1 }}</ref>
* {{tsl|en|Pregnane X receptor|孕烷 X 受体}}（PXR）激动剂（因而调控 [[CYP3A4|CYP3A4]]、{{tsl|en|P-glycoprotein|P-糖蛋白}}）<ref name="pmid9727070">{{cite journal |vauthors=Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA | title = The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions | journal = J. Clin. Invest. | volume = 102 | issue = 5 | pages = 1016–23 |date=September 1998  | pmid = 9727070 | pmc = 508967 | doi = 10.1172/JCI3703 | url = }}</ref><ref name="pmid16863430">{{cite journal |vauthors=Christians U, Schmitz V, Haschke M | title = Functional interactions between P-glycoprotein and CYP3A in drug metabolism | journal = Expert Opin Drug Metab Toxicol | volume = 1 | issue = 4 | pages = 641–54 |date=December 2005  | pmid = 16863430 | doi = 10.1517/17425255.1.4.641 | url = }}</ref>

醋酸环丙孕酮的孕激素和抗雄激素作用等强，<ref name="RunnebaumRabe2012">{{cite book|author1=Benno Clemens Runnebaum|author2=Thomas Rabe|author3=Ludwig Kiesel|title=Female Contraception: Update and Trends|url=http://books.google.com/books?id=LtT6CAAAQBAJ&pg=PA133|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-73790-9|pages=133–134}}</ref>为{{tsl|en|17α-hydroxyprogesterone||17α-羟基黄体酮}}一族中最强的黄体激素。其强度为的{{tsl|en|hydroxyprogesterone acetate||醋酸羟孕酮}}的1200倍、{{tsl|en|medroxyprogesterone acetate|醋酸甲羟孕酮}}的12倍、{{tsl|en|chlormadinone acetate|醋酸氯地孕酮}}的三倍。<ref name="RunnebaumRabe2012" />17α-羟基黄体酮一族的孕激素极其强效，而醋酸环丙孕酮更是已知最强的孕激素，在[[生物檢定法|生物檢定法]]中有1000倍于[[孕酮|孕酮]]的强度。<ref name="HughesHasan2013">{{cite book|author1=A. Hughes|author2=S. H. Hasan|author3=G. W. Oertel|coauthors=H. E. Voss, F. Bahner, F. Neumann, H. Steinbeck, K.-J. Gräf, J. Brotherton, H. J. Horn, R. K. Wagner|title=Androgens II and Antiandrogens / Androgene II und Antiandrogene|url=http://books.google.com/books?id=7JPsCAAAQBAJ&pg=PA490|date=27 November 2013|publisher=Springer Science & Business Media|isbn=978-3-642-80859-3|pages=489, 491}}</ref>还有文献称CPA是迄今为止“最强力的”抗雄激素。<ref name="HughesHasan2013" />

CPA也可能对[[5α還原酶|5α還原酶]]有轻微的抑制作用，不过目前的证据是稀少而互相矛盾。<ref name="pmid11075290">{{cite journal |vauthors=Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S | title = Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro | journal = Gynecol. Endocrinol. | volume = 14 | issue = 4 | pages = 223–30 | year = 2000 | pmid = 11075290 | doi =  10.3109/09513590009167685}}</ref><ref name="pmid1009901">{{cite journal |vauthors=Stárka L, Sulcová J, Broulík P | title = Effect of cyproterone acetate on the action and metabolism of testosterone in the mouse kidney | journal = Endokrinologie | volume = 68 | issue = 2 | pages = 155–63 | year = 1976 | pmid = 1009901 | doi =  }}</ref><ref name="pmid12600226">{{cite journal |vauthors=Raudrant D, Rabe T | title = Progestogens with antiandrogenic properties | journal = Drugs | volume = 63 | issue = 5 | pages = 463–92 | year = 2003 | pmid = 12600226 | doi =  10.2165/00003495-200363050-00003}}</ref>与[[非那雄胺|非那雄胺]]（一种既定的{{tsl|en|5α-reductase inhibitor|5α還原酶抑制剂}}）合用时，CPA对脱发的疗效远高于单用CPA时的情况——这提示要是CPA真的对5α還原酶有直接抑制作用，也不会多么突出。<ref name="pmid10731531">{{cite journal |vauthors=Tartagni M, Schonauer LM, De Salvia MA, Cicinelli E, De Pergola G, D'Addario V | title = Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism | journal = Fertil. Steril. | volume = 73 | issue = 4 | pages = 718–23 | year = 2000 | pmid = 10731531 | doi =  10.1016/s0015-0282(99)00633-0}}</ref><ref name="pmid11239530">{{cite journal |vauthors=Sahin Y, Dilber S, Keleştimur F | title = Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism | journal = Fertil. Steril. | volume = 75 | issue = 3 | pages = 496–500 | year = 2001 | pmid = 11239530 | doi = 10.1016/s0015-0282(00)01764-7}}</ref>

CPA对{{tsl|en|estrogen receptor|雌激素受体}}（ER）或{{tsl|en|mineralocorticoid receptor|盐皮质激素受体}}（MR）没有什么亲和力。{{Citation needed|time=May 2016}}

CPA还会非选择性地和{{tsl|en|μ-opioid receptor|μ-阿片样肽受体|μ-}}、{{tsl|en|δ-opioid receptor|δ-阿片样肽受体|δ-}}、{{tsl|en|κ-opioid receptor|κ-阿片样肽受体|κ-}}[[阿片样肽受体|阿片样肽受体]]结合，不过与其其它活性相比弱得多—（抑制 <nowiki>[</nowiki><sup>3</sup>H<nowiki>]</nowiki>{{tsl|en|diprenorphine|二丙诺啡}}结合的 IC<sub>50</sub> = 1.62 ± 0.33 µM）。<ref name="pmid9203575">{{cite journal |vauthors=Gutiérrez M, Menéndez L, Ruiz-Gayo M, Hidalgo A, Baamonde A | title = Cyproterone acetate displaces opiate binding in mouse brain | journal = Eur. J. Pharmacol. | volume = 328 | issue = 1 | pages = 99–102 | year = 1997 | pmid = 9203575 | doi =  10.1016/s0014-2999(97)83034-8}}</ref>研究提示CPA激活阿片样肽受体的能力也许可以解释其高剂量下{{tsl|en|sedation|镇静}}的副作用，以及其治疗[[丛集性头痛|丛集性头痛]]的功能。<ref name="pmid9203575" />

=== 抗雄活性 ===

醋酸环丙孕酮是一种较强的雄激素受体（AR）[[競爭性拮抗劑|競爭性拮抗劑]]。<ref name="FiggChau2010" />CPA可以直接阻碍内源性雄激素（如[[睾酮|睾酮]] (T)、[[双氢睾酮|双氢睾酮]] (DHT)）结合、激活雄激素受体，从而阻止其在体内产生雄激素作用。然而和[[螺内酯|螺内酯]]一样，醋酸环丙孕酮、{{tsl|en|chlormadinone acetate|醋酸氯地孕酮}}、{{tsl|en|medroxyprogesterone acetate||醋酸甲羟孕酮}}这样的甾体抗雄激素并非单纯的雄激素受体拮抗剂，而是一种很弱的[[部分激动剂|部分激动剂]]。<ref name="FiggChau2010" /><ref name="pmid2462135">{{cite journal |vauthors=Luthy IA, Begin DJ, Labrie F | title = Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture | journal = J. Steroid Biochem. | volume = 31 | issue = 5 | pages = 845–52 | year = 1988 | pmid = 2462135 | doi =  10.1016/0022-4731(88)90295-6}}</ref><ref name="pmid10715537">{{cite journal |vauthors=Térouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, Orio F, Balaguer P, Sultan C | title = A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects | journal = Mol. Cell. Endocrinol. | volume = 160 | issue = 1-2 | pages = 39–49 | year = 2000 | pmid = 10715537 | doi =  10.1016/s0303-7207(99)00251-8}}</ref><ref name="FritzSperoff2010">{{cite book | author1 = Marc A. Fritz | author2 = Leon Speroff | title = Clinical Gynecologic Endocrinology and Infertility | url = http://books.google.com/books?id=Ll73ZsBKLkwC&pg=PA80 | accessdate = 27 May 2012 | date = 20 December 2010 | publisher = Lippincott Williams & Wilkins | isbn = 978-0-7817-7968-5 | page = 80}}</ref>临床上，醋酸环丙孕酮基本上只展现出其抗雄激素的一面——CPA在受体处替换掉本来可以与之结合的那些[[效能_(药理学)|效能]]的雄激素（T、DHT等），因此其净效应一般都是降低雄激素的生理活性。由于在雄激素受体处CPA仍有较弱的效能，CPA不能像[[氟他胺|氟他胺]]这样的AR沉默拮抗剂完全去除雄激素活性，总是会在一定程度上维持这种活性。

醋酸环丙孕酮激活雄激素受体的能力尽管很弱，也还是足以在没有其他雄激素的情况下促进对雄激素敏感的[[癌|癌症]]——例如[[前列腺癌|前列腺癌]]——生长（使用氟他胺一同治疗可以防止）。<ref name="pmid2462135" /><ref name="pmid10715537" />因此，醋酸环丙孕酮在治疗这种癌症时可能不如非甾体抗雄药中的某些沉默拮抗剂有效。除了<!-- 扶她 -->氟他胺之外，{{tsl|en|bicalutamide|比卡鲁胺|}}和{{tsl|en|enzalutamide|恩杂鲁胺|}}也属于AR沉默拮抗剂。<ref name="FiggChau2010" /><ref name="Kampel2012">{{cite book | author = Lewis J. Kampel | title = Dx/Rx: Prostate Cancer: Prostate Cancer | url = http://books.google.com/books?id=oU1rl6LKbJkC&pg=PA169 | date = 20 March 2012 | publisher = Jones & Bartlett Publishers | isbn = 978-1-4496-8695-6 | page = 169}}</ref>

==== 间接雌激素活性 ====
由于CPA并不与雌激素受体（ER）结合，此药基本不具备[[雌激素|雌激素]]活性（无论直接还是间接），甚至可能因为其抗促性腺激素活性在剂量足够时{{tsl|en|antiestrogen|抗雌激素|表现出抗雌作用}}。不过由于雄激素总体上会抵抗乳房雌激素的作用，单独使用CPA可以在男性中通过抗雄激素活性造成类似于雌激素的乳房女性化效果。无论如何，醋酸环丙孕酮的这种副作用在发生率和严重程度上都远低于非甾体抗雄药的程度。非甾体抗雄药不会降低（甚至会提高）雌激素水平。<ref name="pmid1838080">{{cite journal|title=Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience|url=|journal=Exp. Clin. Endocrinol.|issue=2|doi=10.1055/s-0029-1211103|year=1991|volume=98|pages=71–80|pmid=1838080|vauthors=Neumann F, Kalmus J}}</ref><ref name="pmid9854190">{{cite journal|title=Antiandrogens as monotherapy for prostate cancer|url=|journal=Eur. Urol.|issue=|doi=|year=1998|volume=34 Suppl 3|pages=12–7|pmid=9854190|vauthors=Schröder FH}}</ref>

=== 孕激素 ===
CPA是一种极强的孕激素；<ref name="FritzSperoff2011">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=http://books.google.com/books?id=Ll73ZsBKLkwC&pg=PA561|year=2011|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7968-5|pages=561–}}</ref>之前也提到过, 其是目前已知最强效的孕激素。<ref name="HughesHasan2013" />与低剂量炔雌醇相结合作为激素避孕药，每日只需2 mg醋酸环丙孕酮即可有效。<ref name="FritzSperoff2011" /><ref>{{cite book|title=Pharmacology of the Skin II: Methods, Absorption, Metabolism and Toxicity, Drugs and Diseases|url=http://books.google.com/books?id=GvDxCAAAQBAJ&pg=PA489|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-74054-1|pages=489–}}</ref>

由于其孕激素作用，醋酸环丙孕酮可以大幅增加[[催乳素|催乳素]]分泌、诱导雌性[[普通獼猴|普通獼猴]][[乳腺|乳腺]]发育。<ref name="pmid411573">{{vcite2 journal | vauthors = Herbert DC, Schuppler J, Poggel A, Günzel P, El Etreby MF | title = Effect of cyproterone acetate on prolactin secretion in the female Rhesus monkey | journal = Cell Tissue Res. | volume = 183 | issue = 1 | pages = 51–60 | year = 1977 | pmid = 411573 | doi = 10.1007/bf00219991| url = }}</ref>相应地，研究表明CPA和雌激素配合长期用药能使所有的跨性别女性的乳腺小叶完全发育。<ref name="pmid10632490">{{cite journal | vauthors = Kanhai RC, Hage JJ, van Diest PJ, Bloemena E, Mulder JW | title = Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men | journal = Am. J. Surg. Pathol. | volume = 24 | issue = 1 | pages = 74–80 | year = 2000 | pmid = 10632490 | doi = 10.1097/00000478-200001000-00009| url = http://journals.lww.com/ajsp/Fulltext/2000/01000/Short_Term_and_Long_Term_Histologic_Effects_of.9.aspx}}</ref><ref name="Lawrence2007">{{cite journal|last1=Lawrence|first1=Anne A.|title=Transgender Health Concerns|year=2007|pages=473–505|doi=10.1007/978-0-387-31334-4_19|page=|url=http://link.springer.com/chapter/10.1007/978-0-387-31334-4_19}}</ref><ref name="Rosen2009">{{cite book|author=Paul Peter Rosen|title=Rosen's Breast Pathology|url=http://books.google.com/books?id=_swaovkfRMMC&pg=PA31|year=2009|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7137-5|pages=31–}}</ref>在两位实验对象中观察到了类似[[妊娠|妊娠]]的[[乳腺增生|乳腺增生]]。<ref name="Rosen2009" />同一個研究還發現男性攝護腺癌症患者在服用接受不帶孕激素活性的抗雄藥物且不服用雌激素時，其乳腺只會稍有不完全發育。<ref name="pmid10632490" />因此，上述研究的作者認為跨性別女性要得到類似女性的（包括乳腺小叶在内）完全發育的胸部的話，需要同時接受孕激素和雌激素作用。<ref name="pmid10632490" /><ref name="Lawrence2007" />同时研究者还注意到手术去势后停止使用醋酸环丙孕酮会导致乳腺发育状态还原，说明保持发育后的结构需要持续使用孕激素治疗。<ref name="pmid10632490" />

醋酸环丙孕酮的孕激素作用致使其同时具有抗促性腺激素作用。<ref name="FiggChau2010" /><ref name="FritzSperoff2011" />

==== 抗促性腺激素 ====
CPA有强{{tsl|en|antigonadotropic|抗促性腺激素|}}作用，<ref name="FiggChau2010" />能够抑制人类由[[促性腺激素释放激素|促性腺激素释放激素]]（GnRH）诱发分泌的[[促性腺激素|促性腺激素]]过程，<ref name="pmid769466">{{cite journal|title=The effect of cyproterone acetate on the plasma gonadotrophin response to gonadotrophin releasing hormone|date=April 1976|journal=Acta Endocrinologica|issue=4|doi=|volume=81|pages=680–4|pmid=769466|vauthors=Donald RA, Espiner EA, Cowles RJ, Fazackerley JE}}</ref>因而显著降低血浆中[[黄体生成素|黄体生成素]]（LH）和[[促卵泡激素|促卵泡激素]]（FSH）的浓度。由此也使[[孕酮|孕酮]]（P4）、[[雄烯二酮|雄烯二酮]]、睾酮、二氢睾酮、[[雌二醇|雌二醇]]（E2）浓度显著降低；[[性激素结合球蛋白|性激素结合球蛋白]]（SHBG）和[[催乳素|催乳素]]含量则会上升。<ref name="pmid6771095">{{cite journal|title=Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men|journal=Contraception|issue=4|doi=10.1016/s0010-7824(80)80017-5|year=1980|volume=21|pages=393–413|pmid=6771095|vauthors=Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J}}</ref><ref name="pmid6458025">{{cite journal|title=Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer|journal=Prostate|issue=3|doi=10.1002/pros.2990020310|year=1981|volume=2|pages=315–22|pmid=6458025|vauthors=Rost A, Schmidt-Gollwitzer M, Hantelmann W, Brosig W}}</ref><ref name="pmid6777092">{{cite journal|title=The effect of cyproterone acetate on serum testosterone, LH, FSH, and prolactin in male sexual offenders|url=https://archive.org/details/sim_clinical-endocrinology_1980-08_13_2/page/189|journal=Clin. Endocrinol. (Oxf)|issue=2|doi=10.1111/j.1365-2265.1980.tb01041.x|year=1980|volume=13|pages=189–95|pmid=6777092|vauthors=Jeffcoate WJ, Matthews RW, Edwards CR, Field LH, Besser GM}}</ref><ref name="pmid8719011">{{cite journal|title=[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization]|journal=Geburtshilfe Frauenheilkd|issue=11|doi=10.1055/s-2007-1022355|year=1994|volume=54|pages=634–45|language=de|pmid=8719011|vauthors=Grunwald K, Rabe T, Schlereth G, Runnebaum B}}</ref><ref name="pmid6237068">{{cite journal|title=Treatment of idiopathic hirsute women with two combinations of cyproterone acetate|journal=Int J Clin Pharmacol Res|issue=2|doi=|year=1983|volume=3|pages=129–35|pmid=6237068|vauthors=Salva P, Morer F, Ordoñez J, Rodriguez J}}</ref>CPA的抗促性腺激素活性由孕酮受体过激活诱发，<ref name="IversenMelezinek2001" /><ref name="FiggChau2010" /><ref name="FritzSperoff2011" />不过CPA的[[甾體|甾體]][[酶|酶]]抑制作用可能参与了其降低[[性类固醇|性类固醇]]水平的作用。<ref name="pmid7166160">{{cite journal|title=Effects of cyproterone on the steroid biosynthesis in the human ovary in vitro|journal=Endokrinologie|issue=3|doi=|year=1982|volume=80|pages=281–6|pmid=7166160|vauthors=Schürenkämper P, Lisse K}}</ref>

=== 其他活性 ===

==== 糖皮质激素 ====
由于[[下丘脑-垂体-肾上腺轴|下丘脑-垂体-肾上腺轴]]（HPA）的[[负反馈|负反馈]]作用，施用[[强的松|强的松]]和[[地塞米松|地塞米松]]等外源性[[糖皮质激素|糖皮质激素]]会抑制[[腦下垂體|腦下垂體]]分泌[[促腎上腺皮質激素|促腎上腺皮質激素]]，从而抑制[[腎上腺|腎上腺]]分泌[[皮質醇|皮質醇]]，导致肾上腺抑制和[[萎縮|萎縮]]。此时停止施用糖皮质激素会导致一过性的肾上腺功能不全。CPA同样能够稍微降低ACTH、皮质醇水平，诱发肾上腺萎缩，且在停药后也会造成人类和动物肾上腺功能不全，说明其也具有一些糖皮质激素作用。<ref name="pmid233676">{{Vcite2 journal|vauthors=Girard J, Baumann JB, Bühler U, Zuppinger K, Haas HG, Staub JJ, Wyss HI|title=Cyproteroneacetate and ACTH adrenal function|journal=J. Clin. Endocrinol. Metab.|volume=47|issue=3|pages=581–6|year=1978|pmid=233676|doi=10.1210/jcem-47-3-581|url=}}</ref><ref name="pmid438696">{{Vcite2 journal|vauthors=Panesar NS, Herries DG, Stitch SR|title=Effects of cyproterone and cyproterone acetate on the adrenal gland in the rat: studies in vivo and in vitro|journal=J. Endocrinol.|volume=80|issue=2|pages=229–38|year=1979|pmid=438696|doi=10.1677/joe.0.0800229|url=}}</ref><ref name="pmid487397">{{Vcite2 journal|vauthors=El Etreby MF|title=Effect of cyproterone acetate, levonorgestrel and progesterone on adrenal glands and reproductive organs in the beagle bitch|journal=Cell Tissue Res.|volume=200|issue=2|pages=229–43|year=1979|pmid=487397|doi=10.1007/bf00236416|url=}}</ref><ref name="pmid6260040">{{Vcite2 journal|vauthors=Savage DC, Swift PG|title=Effect of cyproterone acetate on adrenocortical function in children with precocious puberty|journal=Arch. Dis. Child.|volume=56|issue=3|pages=218–22|year=1981|pmid=6260040|pmc=1627152|doi=10.1136/adc.56.3.218|url=}}</ref><ref name="pmid6279337">{{Vcite2 journal|vauthors=Stivel MS, Kauli R, Kaufman H, Laron Z|title=Adrenocortical function in children with precocious sexual development during treatment with cyproterone acetate|journal=Clin. Endocrinol. (Oxf)|volume=16|issue=2|pages=163–9|year=1982|pmid=6279337|doi=10.1111/j.1365-2265.1982.tb03160.x|url=}}</ref><ref name="pmid6216913">{{Vcite2 journal|vauthors=Hague WM, Munro DS, Sawers RS, Duncan SL, Honour JW|title=Long-term effects of cyproterone acetate on the pituitary adrenal axis in adult women|journal=Br J Obstet Gynaecol|volume=89|issue=12|pages=981–4|year=1982|pmid=6216913|doi=10.1111/j.1471-0528.1982.tb04650.x|url=}}</ref>矛盾的是，CPA在[[In_vitro|体外]]是糖皮质激素受体（GR）[[受体拮抗剂|拮抗剂]]，<ref name="pmid12695529">{{Cite journal|title=Glucocorticoid receptor antagonism by cyproterone acetate and RU486|author=Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain RE, Cornell W, Steele R, Schweitzer R, Schumacher C|journal=Mol. Pharmacol.|issue=5|doi=10.1124/mol.63.5.1012|year=2003|volume=63|pages=1012–20|pmid=12695529}}</ref><ref name="pmid2875214">{{Vcite2 journal|vauthors=Mercier L, Miller PA, Simons SS|title=Antiglucocorticoid steroids have increased agonist activity in those hepatoma cell lines that are more sensitive to glucocorticoids|journal=J. Steroid Biochem.|volume=25|issue=1|pages=11–20|year=1986|pmid=2875214|doi=10.1016/0022-4731(86)90275-x|url=}}</ref><ref name="pmid1645605">{{Cite journal|title=Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids|author=Poulin R, Baker D, Poirier D, Labrie F|journal=Breast Cancer Research and Treatment|issue=3|doi=10.1007/BF01806369|year=1991|volume=17|pages=197–210|pmid=1645605}}</ref>且能够通过抑制3β-羟基类固醇脱氢酶和21-羟化酶抑制肾上腺生产皮质醇和[[皮质酮|皮质酮]]，<ref name="pmid438696">{{Vcite2 journal|vauthors=Panesar NS, Herries DG, Stitch SR|title=Effects of cyproterone and cyproterone acetate on the adrenal gland in the rat: studies in vivo and in vitro|journal=J. Endocrinol.|volume=80|issue=2|pages=229–38|year=1979|pmid=438696|doi=10.1677/joe.0.0800229|url=}}</ref><ref name="pmid6237971">{{Vcite2 journal|vauthors=Pham-Huu-Trung MT, de Smitter N, Bogyo A, Girard F|title=Effects of cyproterone acetate on adrenal steroidogenesis in vitro|journal=Horm. Res.|volume=20|issue=2|pages=108–15|year=1984|pmid=6237971|doi=10.1159/000179982|url=}}</ref><ref name="pmid2988566">{{Vcite2 journal|vauthors=Lambert A, Mitchell RM, Robertson WR|title=On the site of action of the anti-adrenal steroidogenic effect of cyproterone acetate|journal=Biochem. Pharmacol.|volume=34|issue=12|pages=2091–5|year=1985|pmid=2988566|doi=10.1016/0006-2952(85)90400-9|url=}}</ref><ref name="pmid208851">{{Vcite2 journal|vauthors=Heinze F, Teller WM, Fehm HL, Joos A|title=The effect of cyproterone acetate on adrenal cortical function in children with precocious puberty|journal=Eur. J. Pediatr.|volume=128|issue=2|pages=81–8|year=1978|pmid=208851|doi=10.1007/bf00496993|url=}}</ref>因而表现出抗糖皮质激素活性。这个矛盾或许可以通过分析醋酸环丙孕酮的[[活性代謝產物|活性代謝產物]]解开：CPA的一些代谢产物，例如15β-羟基醋酸环丙孕酮（人类中的血清浓度为CPA原药两倍<ref name="pmid3160716">{{Vcite2 journal|vauthors=Frith RG, Phillipou G|title=15-Hydroxycyproterone acetate and cyproterone acetate levels in plasma and urine|journal=J. Chromatogr.|volume=338|issue=1|pages=179–86|year=1985|pmid=3160716|doi=10.1016/0378-4347(85)80082-7|url=}}</ref>），<ref name="pmid413211">{{Vcite2 journal|vauthors=Bhargava AS, Seeger A, Günzel P|title=Isolation and identification of 15-beta-hydroxy cyproterone acetate as a new metabolite of cyproterone acetate in dog, monkey and man|journal=Steroids|volume=30|issue=3|pages=407–18|year=1977|pmid=413211|doi=10.1016/0039-128x(77)90031-9|url=}}</ref>是糖皮质激素[[激动剂|激动剂]]。<ref name="pmid6266428">{{Vcite2 journal|vauthors=Bhargava AS, Kapp JF, Poggel HA, Heinick J, Nieuweboer B, Günzel P|title=Effect of cyproterone acetate and its metabolites on the adrenal function in man, rhesus monkey and rat|journal=Arzneimittelforschung|volume=31|issue=6|pages=1005–9|year=1981|pmid=6266428|doi=|url=}}</ref>由此可以假设这些产物总体的糖皮质激素活性盖过了CPA本身的抗糖皮质激素活性。环丙孕酮及其醋酸酯CPA通过各自的代谢产物都表现出糖皮质激素活性。基于小鼠研究，CPA的糖皮质激素活性强度大约为强的松的1/5。<ref name="pmid1204803">{{Vcite2 journal|vauthors=Broulik PD, Starka L|title=Corticosteroid-like effect of cyproterone and cyproterone acetate in mice|journal=Experientia|volume=31|issue=11|pages=1364–5|year=1975|pmid=1204803|doi=10.1007/bf01945829|url=}}</ref>

即使不少研究都显示醋酸环丙孕酮会显著造成皮质醇和ACTH相应降低，也有些研究报告即使剂量很高也没有这种效果。<ref name="pmid6266428">{{Vcite2 journal|vauthors=Bhargava AS, Kapp JF, Poggel HA, Heinick J, Nieuweboer B, Günzel P|title=Effect of cyproterone acetate and its metabolites on the adrenal function in man, rhesus monkey and rat|journal=Arzneimittelforschung|volume=31|issue=6|pages=1005–9|year=1981|pmid=6266428|doi=|url=}}</ref><ref name="pmid6257015">{{Vcite2 journal|vauthors=van Wayjen RG, van den Ende A|title=Effect of cyproterone acetate on pituitary-adrenocortical function in man|journal=Acta Endocrinol.|volume=96|issue=1|pages=112–22|year=1981|pmid=6257015|doi=10.1530/acta.0.0960112|url=}}</ref><ref name="pmid2421511">{{Vcite2 journal|vauthors=Schürmeyer T, Graff J, Senge T, Nieschlag E|title=Effect of oestrogen or cyproterone acetate treatment on adrenocortical function in prostate carcinoma patients|journal=Acta Endocrinol.|volume=111|issue=3|pages=360–7|year=1986|pmid=2421511|doi=10.1530/acta.0.1110360|url=}}</ref><ref name="pmid7584530">{{Vcite2 journal|vauthors=van Wayjen RG, van den Ende A|title=Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects|journal=Exp. Clin. Endocrinol. Diabetes|volume=103|issue=4|pages=241–51|year=1995|pmid=7584530|doi=10.1055/s-0029-1211357|url=}}</ref><ref name="pmid6227191">{{Vcite2 journal|vauthors=Holdaway IM, Croxson MS, Evans MC, France J, Sheehan A, Wilson T, Ibbertson HK|title=Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism|journal=Acta Endocrinol.|volume=104|issue=2|pages=222–6|year=1983|pmid=6227191|doi=10.1530/acta.0.1040222|url=}}</ref>

{{tsl|en|Megestrol acetate|醋酸甲地孕酮|}}、{{tsl|en|medroxyprogesterone acetate|醋酸甲羟孕酮}}、{{tsl|en|chlormadinone acetate|醋酸氯地孕酮}}、类固醇黄体素和醋酸环丙孕酮的一些{{tsl|en|structural analog|结构似体}}都有类似地糖皮质激素作用，因此都可能在停药时造成肾上腺功能不全。<ref name="Thomas1997">{{cite book|author=John A. Thomas|title=Endocrine Toxicology, Second Edition|url=http://books.google.com/books?id=URc5JMoNirgC&pg=PA152|date=12 March 1997|publisher=CRC Press|isbn=978-1-4398-1048-4|pages=152–}}</ref><ref name="Panay2015">{{cite book|author=Nick Panay|title=Managing the Menopause|url=http://books.google.com/books?id=l0pLCgAAQBAJ&pg=PA126|date=31 August 2015|publisher=Cambridge University Press|isbn=978-1-107-45182-7|pages=126–}}</ref>

== 藥物代謝 ==
CPA的[[親脂性|親脂性]]使其[[药物代谢动力学|药物代谢动力学]]特性复杂许多。虽然对于CPA的平均[[生物半衰期|生物半衰期]]一般估計為40小时左右，这个时长主要却是反映其在[[脂肪細胞|脂肪細胞]]中的累积过程。从血液中清除CPA的过程相比起来快上很多；脂肪中的储量可能受食物摄入影响。因此，建议按每日分2–3次，或者使用长效注射剂给药。

一部分摄入体内的CPA通过[[水解|水解]]，[[代谢|代谢]]为{{tsl|en|cyproterone|环丙孕酮|}}和[[乙酸|乙酸]]。<ref>{{cite web | author=Medicines and Healthcare products Regulatory Authority | title=Cyproterone Acetate | date=2006-04-11 | url=http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023735.pdf | format=PDF | access-date=2016-06-05 | archive-url=https://web.archive.org/web/20070928010520/http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023735.pdf | archive-date=2007-09-28 | dead-url=yes }}</ref>不过，和其他类固醇[[酯|酯]]不同，CPA并不会被大量水解；其药理活性实际上很多都来自于其原始形式：<ref name=Berlex/>醋酸环丙孕酮的抗雄活性大约为环丙孕酮三倍，<ref>{{cite journal |vauthors=Giorgi EP, Shirley IM, Grant JK, Stewart JC | title = Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate | journal = Biochem J | volume = 132 | issue = 3 | pages = 465–74 | date = 1 March 1973 | pmid = 4125095 | pmc = 1177610 }}</ref>此外环丙孕酮本身完全不带孕激素活性。<ref name="HughesHasan2013" />

CPA由[[CYP3A4|CYP3A4]]代谢，生成[[活性代謝產物|活性代謝產物]][[醋酸15β-羟基环丙孕酮|醋酸15β-羟基环丙孕酮]]。此产物保留了CPA的抗雄活性，孕激素活性则有下降。<ref name="pmid3160716" /><ref>{{cite book | author=Fischl FH. | chapter=Pharmacology of Estrogens and Gestagens. | title=Menopause andropause. | editor=Krause & Pachemegg | year=2001 | pages=33–50 | isbn=3-901299-34-3 | chapterurl=http://www.kup.at/kup/pdf/4975.pdf | format=PDF | publisher=Krause und Pachernegg | location=Gablitz}}</ref><ref>{{cite web |author1=New Zealand Medicines |author2=Medical Devices Safety Authority |title=Data Sheet: Diane 35 ED |date=2005-12-09 |url=http://www.medsafe.govt.nz/Profs/Datasheet/d/Diane35EDtab.htm |deadurl=yes |archiveurl=https://web.archive.org/web/20070108191008/http://medsafe.govt.nz/Profs/Datasheet/d/Diane35EDtab.htm |archivedate=2007-01-08 }}</ref>因此，与抑制CYP3A4的药物一同给药可提升醋酸环丙孕酮的孕激素活性。

=== 吸收 ===
醋酸环丙孕酮的口服[[生物利用率|生物利用率]]被报告为100%。<ref name="pmid16112947" />然而，有说法称醋酸环丙孕酮通过[[消化道|消化道]]吸收较差，所以应该在进食后服用，能提升吸收效率。<ref name="pmid12603397">{{cite journal | vauthors = Anderson J | title = The role of antiandrogen monotherapy in the treatment of prostate cancer | journal = BJU Int. | volume = 91 | issue = 5 | pages = 455–61 | year = 2003 | pmid = 12603397 | doi = 10.1046/j.1464-410x.2003.04026.x| url =https://archive.org/details/sim_bju-international_2003-03_91_5/page/455}}</ref>

=== 分布 ===

=== 代谢 ===

=== 排泄 ===

== 历史 ==
CPA于1960年代早期发现；1962年，[[Schering_AG|Schering AG]]员工鲁道夫·维歇特和身在柏林的F·纽曼申请了一个“黄体激素制剂”的专利（{{US Patent|3234093}}）。专利通过后一年的1966年，纽曼就发表了CPA在大鼠中抗雄作用的证据；此外还报告了CPA对脑有“有组织的效果”。<ref>{{cite journal | vauthors = Neumann F,  Elger W |year=1966 |title=Permanent changes in gonadal function and sexual behaviour as a result of early feminization of male rats by treatment with an antiandrogenic steroid |url= |journal=Endokrinologie |volume=50 |issue= |pages=209–225}}</ref>同年，瑞典[[隆德|隆德]]的一组研究人员发表研究，展示CPA对于雄性胎鼠有导致[[泌尿生殖系统畸形|泌尿生殖系统畸形]]的能力。<ref>{{cite journal | vauthors = Forsberg JG, Jacobsohn D, Norgren A | title = Modifications of reproductive organs in male rats influenced prenatally or pre- and postnatally by an "antiandrogenic" steroid (Cyproterone) | journal = Zeitschrift Für Anatomie Und Entwicklungsgeschichte | volume = 127 | issue = 2 | pages = 175–86 | date = 1968 | pmid = 5692718 | doi = 10.1007/bf00521983 | url = http://www.ncbi.nlm.nih.gov/pubmed/5692718 | publisher = Springer }}</ref>从此，全世界都开始在动物实验中使用CPA研究抗雄激素影响{{tsl|en|sexual differentiation|性分化|}}的程度和方式。

在1970年对于醋酸环丙孕酮进行了最早的人类实验——在口服给药后测量血浆中的药物浓度、精子生产速率<ref>{{Cite journal|title=The effect of orally administered cyproterone on the serum production in human subjects|author=Tamm J, Voigt KD, Schönrock M, Ludwig E|url=|date=Jan 1970|journal=Acta Endocrinol (Copenh).|issue=1|volume=63|pages=50–8|pmid=5467021}}</ref>，还有在女性中测量头发生长速度。1972年，[[精神科醫師|精神科醫師]]开始在“性变态”患者上使用这种药物<ref>{{Cite journal|title=Resocialization of sexually abnormal patients by a combination of anti-androgen administration and psychotherapy|author=Von Schumann HJ|url=|journal=Psychother Psychosom|issue=6|year=1972|volume=20|pages=321–32}}</ref>。1970年代中叶，[[螺内酯|螺内酯]]这类的不带或带有较弱孕激素作用的抗雄药开始出现。在[[亮丙瑞林|亮丙瑞林]]开发出来之前，醋酸环丙孕酮是仅有的几种治疗性早熟的药物。

== 社会与文化 ==

=== 命名 ===
“cyproterone acetate”为醋酸环丙孕酮的[[国际非专利药品名称|INN]]、{{tsl|en|United States Adopted Name||USAN}}、{{tsl|en|British Approved Name||BAN}}、{{tsl|en|Japanese Accepted Name||JAN}}命名。此物质也可称为1,2α-亚甲基-6-氯-δ<sup>6</sup>-17α-乙酰氧基黄体酮。

醋酸环丙孕酮与{{tsl|en|ethinyl estradiol|炔雌醇}}的复方制剂的商品在全球大部分地方名为“-{zh-cn:达英-35; zh-tw:黛麗安}-”（Diane-35），在[[英国|英国]]名为 Dianette，在[[德国|德国]]名为 Bella Hexal，在[[瑞典|瑞典]]名为 Diane，在[[智利|智利]]名为 Dixi-35。<ref name="HumansOrganization2007"/>

== 参见 ==
* {{tsl|en|Anagestone acetate|醋酸阿那孕酮|}}
* {{tsl|en|Chlormadinone acetate|醋酸氯地孕酮|}}
* {{tsl|en|Delmadinone acetate||}}
* {{tsl|en|Drospirenone|屈螺酮|}}
* {{tsl|en|Hydroxyprogesterone caproate|己酸羟孕酮|}}
* {{tsl|en|Medroxyprogesterone acetate|醋酸甲羟孕酮|}}
* {{tsl|en|Megestrol acetate|醋酸甲地孕酮|}}
* {{tsl|en|Melengestrol acetate|醋酸美伦孕酮|}}
* [[螺内酯|螺内酯]]

== 引用 ==
{{Reflist|3|}}

{{Progestogens and antiprogestogens}}

[[Category:抗雄激素物质|Category:抗雄激素物质]]
[[Category:糖皮质激素|Category:糖皮质激素]]
[[Category:有机氯化合物|Category:有机氯化合物]]
[[Category:孕激素类|Category:孕激素类]]
[[Category:甾族化合物|Category:甾族化合物]]
[[Category:跨性別與醫學|Category:跨性別與醫學]]
[[Category:肝毒素|Category:肝毒素]]
{{Progesterone receptor modulators}}